Custom-Made vaccine takes on deadly brain cancer
NCT ID NCT02287428
First seen Mar 14, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This early-phase study tests whether a personalized vaccine made from a patient's own tumor mutations can safely boost the immune system to fight glioblastoma, an aggressive brain cancer. About 56 newly diagnosed patients receive the vaccine along with radiation and sometimes the immunotherapy drug pembrolizumab. The goal is to see if the vaccine is safe and can trigger an immune response against the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02113, United States
Conditions
Explore the condition pages connected to this study.